Drugs

PEER-REVIEWED FEATURE

Mavacamten: Adis Evaluation

Key Points

- A cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of HCM and diseases of diastolic dysfunction
- Received its first approval on 28 April 2022 in the USA
- Approved for use in the treatment of adults with symptomatic NYHA class II-III obstructive HCM to improve functional capacity and symptoms

Summary

Mavacamten (Camzyos™) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction.

In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms.

This article summarizes the milestones in the development of mavacamten leading to this first approval for the treatment of adults with symptomatic NYHA class II-III obstructive HCM.

Keam, S.J. Drugs. 2022. https://doi.org/10.1007/s40265-022-01739-7